155 related articles for article (PubMed ID: 37077837)
21. Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis.
Sun L; Tuo Z; Chen X; Wang H; Lyu Z; Li G
Heliyon; 2024 Mar; 10(6):e27628. PubMed ID: 38510027
[TBL] [Abstract][Full Text] [Related]
22. Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer.
Wu M; Li X; Zhang T; Liu Z; Zhao Y
Front Oncol; 2019; 9():996. PubMed ID: 31612115
[No Abstract] [Full Text] [Related]
23. Identification and validation of a lipid metabolism gene signature for predicting biochemical recurrence of prostate cancer after radical prostatectomy.
Cai Y; Lin J; Wang Z; Ma Y; Pan J; Liu Y; Zhao Z
Front Oncol; 2022; 12():1009921. PubMed ID: 36324578
[TBL] [Abstract][Full Text] [Related]
24. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
25. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
26. Identification of a Four Cancer Stem Cell-Related Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Adenocarcinoma.
Li S; Chen R; Luo W; Lin J; Chen Y; Wang Z; Lin W; Li B; Wang J; Yang J
Comb Chem High Throughput Screen; 2022; 25(12):2070-2081. PubMed ID: 35048799
[TBL] [Abstract][Full Text] [Related]
27. FCGR3A: A new biomarker with potential prognostic value for prostate cancer.
Zha Z; Hong Y; Tang Z; Du Q; Wang Y; Yang S; Wu Y; Tan H; Jiang F; Zhong W
Front Oncol; 2022; 12():1014888. PubMed ID: 36505767
[TBL] [Abstract][Full Text] [Related]
28. A Gleason score-related outcome model for human prostate cancer: a comprehensive study based on weighted gene co-expression network analysis.
Wang Y; Yang Z
Cancer Cell Int; 2020; 20():159. PubMed ID: 32425694
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer.
Yang C; Chen L; Niu Q; Ge Q; Zhang J; Tao J; Zhou J; Liang C
Cancer Cell Int; 2022 Dec; 22(1):382. PubMed ID: 36471446
[TBL] [Abstract][Full Text] [Related]
30. An anoikis-related gene signature for prediction of the prognosis in prostate cancer.
Zhao X; Wang Z; Tang Z; Hu J; Zhou Y; Ge J; Dong J; Xu S
Front Oncol; 2023; 13():1169425. PubMed ID: 37664042
[TBL] [Abstract][Full Text] [Related]
31. A New Prognostic Risk Score: Based on the Analysis of Autophagy-Related Genes and Renal Cell Carcinoma.
He M; Li M; Guan Y; Wan Z; Tian J; Xu F; Zhou H; Gao M; Bi H; Chong T
Front Genet; 2021; 12():820154. PubMed ID: 35237298
[No Abstract] [Full Text] [Related]
32. Establishment of a Novel Combined Nomogram for Predicting the Risk of Progression Related to Castration Resistance in Patients With Prostate Cancer.
Li S; Shi L; Li F; Yao B; Chang L; Lu H; Song D
Front Genet; 2022; 13():823716. PubMed ID: 35620461
[No Abstract] [Full Text] [Related]
33. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer.
Wang Y; Fan J; Chen T; Xu L; Liu P; Xiao L; Wu T; Zhou Q; Zheng Q; Liu C; Chan FL; Wu D
Front Endocrinol (Lausanne); 2022; 13():975623. PubMed ID: 36034466
[TBL] [Abstract][Full Text] [Related]
34. A seven-gene prognosis model to predict biochemical recurrence for prostate cancer based on the TCGA database.
He Y; Zhang J; Chen Z; Sun K; Wu X; Wu J; Sheng L
Front Surg; 2022; 9():923473. PubMed ID: 37255653
[TBL] [Abstract][Full Text] [Related]
35. A 10-gene signature as a predictor of biochemical recurrence after radical prostatectomy in patients with prostate cancer and a Gleason score ≥7.
Wu X; Lv D; Lei M; Cai C; Zhao Z; Eftekhar M; Gu D; Liu Y
Oncol Lett; 2020 Sep; 20(3):2906-2918. PubMed ID: 32782607
[TBL] [Abstract][Full Text] [Related]
36. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
38. A new risk stratification system of prostate cancer to identify high-risk biochemical recurrence patients.
Wu X; Lv D; Eftekhar M; Khan A; Cai C; Zhao Z; Gu D; Liu Y
Transl Androl Urol; 2020 Dec; 9(6):2572-2586. PubMed ID: 33457230
[TBL] [Abstract][Full Text] [Related]
39. Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma.
Zhu S; Lin F; Chen Z; Jiang X; Zhang J; Yang Q; Chen Y; Wang J
Front Genet; 2020; 11():563882. PubMed ID: 33101383
[TBL] [Abstract][Full Text] [Related]
40. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
